United States 2022-2025 M&A Law Firm Hourly Rate Report: Focus on Mergers & Acquisitions, Capital Markets, and Private Equity Practice for the AMLAW 10 to AMLAW 200 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Valeo 2022-2025 M&A Law Firm Hourly Rate Report” report has been added to ResearchAndMarkets.com’s... Read more.
Citizens Financial Group, Inc. Announces an Increase in Common Share Repurchase Authorization to $1.5 billion
PROVIDENCE, R.I.–(BUSINESS WIRE)–Citizens Financial Group, Inc. (NYSE: CFG or the “Company”) today announces that its board of directors has increased... Read more.
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress
— Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction — — Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction – — Well-Tolerated... Read more.
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
-Data highlights potential of ZL-1503 as a promising treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases -Favorable preclinical... Read more.
Quinbrook Strengthens Leadership Structure to Support Future Growth
Announces New Global CEO and Regional Leader for North America NEW YORK–(BUSINESS WIRE)–Quinbrook Infrastructure Partners (“Quinbrook”), a specialist... Read more.
CI Global Asset Management Announces June 2025 Distributions for the CI ETFs
NOT FOR DISSEMINATION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA TORONTO–(BUSINESS WIRE)–$CIX #CIFinancial—CI... Read more.
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors... Read more.
Booz Allen Hamilton to Host Conference Call to Discuss First Quarter Fiscal 2026 Results on Friday, July 25, 2025
MCLEAN, Va.–(BUSINESS WIRE)–$BAH #earnings–Booz Allen Hamilton Holding Corporation (NYSE: BAH), the parent company of advanced technology company... Read more.
Cloudflare, Inc. Announces Pricing of Offering of $1.75 Billion of 0% Convertible Senior Notes Due 2030
SAN FRANCISCO–(BUSINESS WIRE)–Cloudflare, Inc. (“Cloudflare”) (NYSE: NET) today announced the pricing of $1.75 billion aggregate principal amount... Read more.
Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms
Partnership further validates Ethris’ novel technology platform based on stabilized non-immunogenic mRNA, which overcomes the innate instability and immunity of... Read more.